TherapeuticsMD (TXMD) Appoints Hugh O’Dowd as CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
November 11, 2021 6:45 AM EST- Mr. ODowd to succeed Robert G. Finizio, effective on or before December 31, 2021 -
- Mr. Finizio appointed Vice Chair of the Board -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading womens healthcare company, today announced key leadership changes, including the appointment of Hugh ODowd, the Companys current President, as the Companys Chief Executive Officer and member of the board of directors. Mr. ODowd will succeed Robert G. Finizio, the Companys Co-founder and... More
